Ryan Allway August 23rd, 2022 Psychedelics, Top News Based on over 20 years of pioneering Yale University research, clinical development currently underway to create and develop viable and efficacious treatment alternatives for patients with major depressive disorder by leveraging the known pharmacology of ketamine and psychedelic-based therapeutics SAN FRANCISCO, August... Read more
Ryan Allway August 23rd, 2022 Psychedelics, Top News Springfield, Oregon–(Newsfile Corp. – August 23, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) (“Silo Wellness” or the “Company”), a leading global psychedelics company, is pleased to announce that it has opened its first ecotourism microdosing psilocybin resort... Read more
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
August 17, 2022
Ryan Allway August 17th, 2022 Psychedelics, Top News TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced... Read more
VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, has received permission from Health Canada to manufacture and distribute additional psychedelic substances, most... Read more
Ryan Allway August 15th, 2022 Psychedelics, Top News Vermont ketamine treatment facility added to fast-growing chain of psychedelic mental-health clinics LOS ANGELES, Aug. 15, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of its first Vermont clinic, continuing what has... Read more
Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle
August 8, 2022
Ryan Allway August 8th, 2022 Psychedelics, Top News VANCOUVER, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as... Read more
Irwin Naturals Completes Georgia Acquisition, Adds Two Ketamine Clinics to National Chain
August 8, 2022
Ryan Allway August 8th, 2022 Psychedelics, Top News The national chain of psychedelic mental-healthcare clinics growing rapidly LOS ANGELES, Aug. 08, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of two ketamine clinics in Georgia through an asset purchase of... Read more
Ryan Allway July 28th, 2022 Psychedelics, Top News Company’s national rollup accelerating with acquisition of New Hampshire ketamine clinic LOS ANGELES, July 28, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of the assets of New England Ketamine, which is... Read more
Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
July 27, 2022
Ryan Allway July 27th, 2022 News, Psychedelics, Top Story Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached... Read more
